Recently, it was shown that infiltration of T cells, including CD8+ and effector memory CD4+, was significantly increased in tumors that responded to cetuximab, and this increase was independent of tumor mutation load or neoantigen burden [13], suggesting that T‐cell infiltration was not due to immunogenic cell death following cetuximab exposure. The gene discussed is CD4; the disease is neoplasm.